Seagen Inc.

Seagen Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1998-01-01
Employees
3.2K
Market Cap
-
Website
http://www.seagen.com

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

First Posted Date
2018-02-07
Last Posted Date
2020-02-25
Lead Sponsor
Seagen Inc.
Registration Number
NCT03424473

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2017-12-20
Last Posted Date
2019-09-18
Lead Sponsor
Seagen Inc.
Target Recruit Count
14
Registration Number
NCT03379584
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

University of California at San Francisco, San Francisco, California, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 3 locations

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

First Posted Date
2017-10-16
Last Posted Date
2024-12-20
Lead Sponsor
Seagen Inc.
Target Recruit Count
186
Registration Number
NCT03310957
Locations
🇩🇪

Marien Hospital Bottrop, Bottrop, Other, Germany

🇩🇪

Klinikum der Universitat Munchen, Munchen, Other, Germany

🇰🇷

Samsung Medical Center, Seoul, Other, Korea, Republic of

and more 47 locations

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

First Posted Date
2017-08-10
Last Posted Date
2021-11-04
Lead Sponsor
Seagen Inc.
Target Recruit Count
5
Registration Number
NCT03245736
Locations
🇬🇧

Fiona Thistlethwaite, Manchester, United Kingdom

🇬🇧

Johann de Bono, Chelsea, United Kingdom

🇺🇸

Brian Slomovitz, Miami, Florida, United States

and more 1 locations

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

First Posted Date
2017-02-06
Last Posted Date
2024-11-26
Lead Sponsor
Seagen Inc.
Target Recruit Count
117
Registration Number
NCT03043313
Locations
🇺🇸

Texas Oncology - Beaumont, Beaumont, Texas, United States

🇺🇸

Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States

🇪🇸

Hospital General Universitario Gregorio Maranon, Madrid, Other, Spain

and more 53 locations

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2016-11-03
Last Posted Date
2019-08-12
Lead Sponsor
Seagen Inc.
Target Recruit Count
27
Registration Number
NCT02954796
Locations
🇺🇸

Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 8 locations

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

First Posted Date
2016-11-02
Last Posted Date
2019-07-19
Lead Sponsor
Seagen Inc.
Target Recruit Count
47
Registration Number
NCT02952989
Locations
🇺🇸

University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

and more 8 locations

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

First Posted Date
2016-08-04
Last Posted Date
2019-03-11
Lead Sponsor
Seagen Inc.
Target Recruit Count
24
Registration Number
NCT02855359
Locations
🇵🇷

Ponce Medical School Foundation, Ponce, Puerto Rico

🇺🇸

Hollings Cancer Center, Charleston, South Carolina, United States

🇺🇸

Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 32 locations

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2016-07-28
Last Posted Date
2018-05-14
Lead Sponsor
Seagen Inc.
Target Recruit Count
17
Registration Number
NCT02848248
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

MD Anderson Cancer Center / University of Texas, Houston, Texas, United States

and more 4 locations

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2016-05-30
Last Posted Date
2018-12-12
Lead Sponsor
Seagen Inc.
Target Recruit Count
240
Registration Number
NCT02785900
Locations
🇺🇸

University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

LSU Health Sciences Center / Feist Weiller Cancer Center, Shreveport, Louisiana, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

and more 125 locations
© Copyright 2024. All Rights Reserved by MedPath